1CM
ALDX icon

1492 Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

1492 Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-223,317
Closed -$1.16M – 131
2025
Q4 		$1.16M Buy
+223,317
New +$1.15M 0.44% 63

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

1492 Capital Management's ALDX Position: Q1 2026 in Review

1492 Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 223,317 shares — an estimated $1.16M sold.

1492 Capital Management first reported a position in ALDX in Q4 2025 and held it in 1 quarter. The position peaked at $1.16M in Q4 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • 1492 Capital Management reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • 1492 Capital Management sold 223,317 Aldeyra Therapeutics shares in Q1 2026, an estimated $1.16M.
  • 1492 Capital Management first reported a position in Aldeyra Therapeutics in Q4 2025 and held it in 1 quarter.
  • 1492 Capital Management's Aldeyra Therapeutics position peaked at $1.16M in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on 1492 Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.